Consejo Nacional de Salud

28 Zheng M, Chen Y, Bai J, Xin Y, Pan X, Zhao L.
Meta-analysis of prophylactic allopurinol use in
post-endoscopic retrograde cholangiopancreatography,
Department of Infection and Liver Diseases,
The First Affiliated Hospital of Wenzhou
Medical College, Wenzhou, China.
29 Vries, M, Franck U, Libreram A, Sperling O, Allopurinol
un the prophylaxis of uric acid stones.
Form the metabolic unit of the deparment of medicin
D, tel Aviv University Medical school, Bailison
Hospital , Petech Tikva, Isarael, disponible en:
http://www.pubmedcentral.nih.gov/ picrender.
fcgi?artid=2453421&blob type=pdf
30 Schlesinger N, Schumacher R, Catton M, Maxwell
L. Colchicine for acute gout. Cochrane Database
of Systematic Reviews 2006, Issue 4. Art. No.:
CD006190. DOI:10.1002/14651858. CD006190.
Disponible en: http://www.mrw.interscience. wiley.com/cochrane/clsysrev/articles
/CD006190/
frame.html
31 Levy M, Eldor A, Zylber-Katz E, Eliakim M ,The effect
of long-term colchicine therapy in patients with
recurrent polyserositis on the capacity of blood
platelets to synthesize thromboxane A2. Clinical
Pharmacology Unit, Department of Medicine
A and 'Department of Haematology, Hadassah
University Hospital, Jerusalem, Israel 91120 , Disponible
en: http://www.pubmedcentral.nih.gov/
picrender.fcgi?artid=1427989&blobtype=pdf
32 Reid D, Hosking D, Kendler D, Brandi M, Wark J
D, Weryha J, Marques-Neto J, Gaines K, Verbruggen
N, Melton M E, Alendronic Acid Produces
Greater Effects Than Risedronic Acid on Bone
Density and Turnover in Postmenopausal Women
With Osteoporosis, disponible en: http://www.
mrw.interscience.wiley .com/cochrane/clcentral/
articles/422/CN-00574422/frame.html
33 Wells G, Cranney A, Peterson J, Boucher M, Shea
B, Welch B, Coyle D, Tugwell P, Alendronate
for the primary and secondary prevention of osteoporotic
fractures in postmenopausal women
, Cardiovascular Research Reference Centre,
University of Ottawa Heart Institute, Ottawa,
Canada. Epidemiology and Community Medicine,
Ottawa Health Research Institute, Ottawa, Canadahttp://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD001155/frame.html
34 Delmas PD, Adami S, Strugala C, Stakkestad
JA, Reginster JY, Felsenberg D, Christiansen C,
Civitelli R, Drezner MK, Recker RR, Bolognese
M, Hughes C, Masanauskaite D, Ward P, Sambrook
P, Reid DM. Intravenous ibandronate
injections in postmenopausal women with osteoporosis:
one-year results from the dosing intravenous
administration study. Université Claude
Bernard Lyon 1 and INSERM Research Unit
403, Lyon, France, disponible en: http://www.
ncbi.nlm.nih.gov/ pubmed/16729277?ordinalpos
=13&itool=EntrezSystem2.PEntrez. Pubmed.
Pubmed_ResultsPanel.Pubmed _DefaultReport-
Panel.Pubmed_RVDocSum
35 Miller PD, Epstein S, Sedarati F, Reginster JY.
nce-monthly oral ibandronate compared with
weekly oral alendronate in postmenopausal osteoporosis:
results from the head-to-head MO-
TION study Colorado Center for Bone Research,
Lakewood, Colorado 80227, USA. Disponible
en: http://www.ncbi.nlm.nih.gov/pubmed/
18069036?ordinalpos=39&itool= EntrezSystem2.
PEntrez.Pubmed. Pubmed_ResultsPanel.Pubmed_
Default ReportPanel.Pubmed_RVDocSum
GRUPO M | Sistema músculo esquelético
421
M